van Vliet AA - Search Results

1

Boosting Natural Killer Cell Therapies in Glioblastoma Multiforme Using Supramolecular Cationic Inhibitors of Heat Shock Protein 90.

Saha T, van Vliet AA, Cui C, Macias JJ, Kulkarni A, Pham LN, Lawler S, Spanholtz J, Georgoudaki AM, Duru AD, Goldman A. Saha T, et al. Among authors: van vliet aa. Front Mol Biosci. 2021 Dec 1;8:754443. doi: 10.3389/fmolb.2021.754443. eCollection 2021. Front Mol Biosci. 2021. PMID: 34926577 Free PMC article.

2

Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma.

van Vliet AA, Georgoudaki AM, Raimo M, de Gruijl TD, Spanholtz J. van Vliet AA, et al. Cancers (Basel). 2021 Sep 21;13(18):4722. doi: 10.3390/cancers13184722. Cancers (Basel). 2021. PMID: 34572949 Free PMC article. Review.

3

Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor.

Toffoli EC, Sheikhi A, Lameris R, King LA, van Vliet A, Walcheck B, Verheul HMW, Spanholtz J, Tuynman J, de Gruijl TD, van der Vliet HJ. Toffoli EC, et al. Cancers (Basel). 2021 Oct 29;13(21):5446. doi: 10.3390/cancers13215446. Cancers (Basel). 2021. PMID: 34771609 Free PMC article.

4

Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34⁺ progenitor cell-derived NK cells.

van Vliet AA, Peters E, Vodegel D, Steenmans D, Raimo M, Gibbs S, de Gruijl TD, Duru AD, Spanholtz J, Georgoudaki AM. van Vliet AA, et al. iScience. 2023 Jun 9;26(7):107078. doi: 10.1016/j.isci.2023.107078. eCollection 2023 Jul 21. iScience. 2023. PMID: 37426355 Free PMC article.

5

Allogeneic NK cells induce monocyte-to-dendritic cell conversion, control tumor growth, and trigger a pro-inflammatory shift in patient-derived cultures of primary and metastatic colorectal cancer.

Toffoli EC, van Vliet AA, Verheul HWM, van der Vliet HJ, Tuynman J, Spanholtz J, de Gruijl TD. Toffoli EC, et al. Among authors: van vliet aa. J Immunother Cancer. 2023 Dec 6;11(12):e007554. doi: 10.1136/jitc-2023-007554. J Immunother Cancer. 2023. PMID: 38056896 Free PMC article.

6

Allogeneic NK cells induce the in vitro activation of monocyte-derived and conventional type-2 dendritic cells and trigger an inflammatory response under cancer-associated conditions.

Toffoli EC, van Vliet AA, Forbes C, Arns AJ, Verheul HWM, Tuynman J, van der Vliet HJ, Spanholtz J, de Gruijl TD. Toffoli EC, et al. Among authors: van vliet aa. Clin Exp Immunol. 2024 Apr 23;216(2):159-171. doi: 10.1093/cei/uxae007. Clin Exp Immunol. 2024. PMID: 38330230 Free PMC article.

7

Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.

Tiessen RG, Kennedy CA, Keller BT, Levin N, Acevedo L, Gedulin B, van Vliet AA, Dorenbaum A, Palmer M. Tiessen RG, et al. Among authors: van vliet aa. BMC Gastroenterol. 2018 Jan 5;18(1):3. doi: 10.1186/s12876-017-0736-0. BMC Gastroenterol. 2018. PMID: 29304731 Free PMC article. Clinical Trial.

8

Total energy expenditure assessed by salivary doubly labelled water analysis and its relevance for short-term energy balance in humans.

Guidotti S, Verstappen-Dumoulin BM, Jansen HG, Aerts-Bijma AT, van Vliet AA, Scheurink AJ, Meijer HA, van Dijk G. Guidotti S, et al. Among authors: van vliet aa. Rapid Commun Mass Spectrom. 2016 Jan 15;30(1):143-50. doi: 10.1002/rcm.7412. Rapid Commun Mass Spectrom. 2016. PMID: 26661981

9

First-in-human study of the pharmacokinetics and antiviral activity of IDX375, a novel nonnucleoside hepatitis C virus polymerase inhibitor.

de Bruijne J, van de Wetering de Rooij J, van Vliet AA, Zhou XJ, Temam MF, Molles J, Chen J, Pietropaolo K, Sullivan-Bólyai JZ, Mayers D, Reesink HW. de Bruijne J, et al. Among authors: van vliet aa. Antimicrob Agents Chemother. 2012 Aug;56(8):4525-8. doi: 10.1128/AAC.00451-12. Epub 2012 Jun 4. Antimicrob Agents Chemother. 2012. PMID: 22664976 Free PMC article. Clinical Trial.

10

Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7.

Boonstra A, Liu BS, Groothuismink ZM, Bergmann JF, de Bruijne J, Hotho DM, Hansen BE, van Vliet AA, van de Wetering de Rooij J, Fletcher SP, Bauman LA, Rahimy M, Appleman JR, Freddo JL, Reesink HW, de Knegt RJ, Janssen HL. Boonstra A, et al. Among authors: van vliet aa. Antivir Ther. 2012;17(4):657-67. doi: 10.3851/IMP2023. Epub 2011 Dec 19. Antivir Ther. 2012. PMID: 22301364

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page